The company's shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...